Insulet | PODD - Sales Revenues


Insulet reported $783.8M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Abbott USD 11.46B 90M Dec/2025
Align Technology USD 1.05B 54.3M Dec/2025
AtriCure USD 140.5M 6.2M Dec/2025
Avanos Medical USD 180.9M 3.1M Dec/2025
Baxter International USD 2.97B 130M Dec/2025
Becton, Dickinson and Co. USD 5.3B 600M Dec/2025
Boston Scientific USD 5.29B 220M Dec/2025
Cardinal Health USD 65.63B 1.63B Dec/2025
Cooper Companies USD 1.07B 4.9M Sep/2025
Dexcom USD 1.26B 50M Dec/2025
Edwards Lifesciences USD 1.57B 20M Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Globus Medical USD 826.4M 57.4M Dec/2025
ICU Medical USD 540.7M 3.7M Dec/2025
Inogen USD 74.93M 504K Sep/2024
Insulet USD 783.8M 77.5M Dec/2025
Integra LifeSciences USD 402.06M 13.54M Sep/2025
J&J USD 24.6B 610M Dec/2025
Masimo USD 371.5M 600K Sep/2025
Medtronic USD 9B 39M Jan/2026
Merit Medical Systems USD 393.9M 9.7M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Solventum Corp USD 2.1B 60M Sep/2025
Stryker USD 7.2B 1.14B Dec/2025
Tandem Diabetes Care USD 290.4M 41.15M Dec/2025
Teleflex USD 913M 132.11M Sep/2025
West Pharmaceutical Services USD 805M 400K Dec/2025
Zimmer Biomet Holdings USD 2.24B 240M Dec/2025